Who are Propranolol - Spironolactone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/propranolol-spironolactone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Propranolol - Spironolactone — Competitive Intelligence Brief

Propranolol - Spironolactone (Propranolol - Spironolactone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-blocker and mineralocorticoid receptor antagonist combination. Area: Cardiovascular.

marketed Beta-blocker and mineralocorticoid receptor antagonist combination Beta-adrenergic receptors (propranolol); mineralocorticoid receptor (spironolactone) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Propranolol - Spironolactone (Propranolol - Spironolactone) — University Hospital, Angers. This combination uses propranolol (a beta-blocker) to reduce heart rate and blood pressure, and spironolactone (an aldosterone antagonist) to promote sodium and water excretion while retaining potassium.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Propranolol - Spironolactone TARGET	Propranolol - Spironolactone	University Hospital, Angers	marketed	Beta-blocker and mineralocorticoid receptor antagonist combination	Beta-adrenergic receptors (propranolol); mineralocorticoid receptor (spironolactone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-blocker and mineralocorticoid receptor antagonist combination class)

University Hospital, Angers · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Propranolol - Spironolactone — Competitive Intelligence Brief. https://druglandscape.com/ci/propranolol-spironolactone. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab